Gupta Amit, Dunlop Alex, Mitchell Adam, McQuaid Dualta, Nill Simeon, Barnes Helen, Newbold Kate, Nutting Chris, Bhide Shreerang, Oelfke Uwe, Harrington Kevin Joseph, Wong Kee Howe
The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Head & Neck Unit, 15 Cotswold Road, Sutton, London SM2 5NG, United Kingdom.
The Joint Department of Physics, The Royal Marsden Hospital and the Institute of Cancer Research; Downs Road, Sutton SM2 5PT, United Kingdom.
Clin Transl Radiat Oncol. 2021 Nov 10;32:48-51. doi: 10.1016/j.ctro.2021.11.001. eCollection 2022 Jan.
The Elekta Unity MR-Linac (MRL) has enabled adaptive radiotherapy (ART) for patients with head and neck cancers (HNC). Adapt-To-Shape-Lite (ATS-Lite) is a novel Adapt-to-Shape strategy that provides ART without requiring daily clinician presence to perform online target and organ at risk (OAR) delineation. In this study we compared the performance of our clinically-delivered ATS-Lite strategy against three Adapt-To-Position (ATP) variants: Adapt Segments (ATP-AS), Optimise Weights (ATP-OW), and Optimise Shapes (ATP-OS).
Two patients with HNC received radical-dose radiotherapy on the MRL. For each fraction, an ATS-Lite plan was generated online and delivered and additional plans were generated offline for each ATP variant. To assess the clinical acceptability of a plan for every fraction, twenty clinical goals for targets and OARs were assessed for all four plans.
53 fractions were analysed. ATS-Lite passed 99.9% of mandatory dose constraints. ATP-AS and ATP-OW each failed 7.6% of mandatory dose constraints. The Planning Target Volumes for 54 Gy (D95% and D98%) were the most frequently failing dose constraint targets for ATP. ATS-Lite median fraction times for Patient 1 and 2 were 40 mins 9 s (range 28 mins 16 s - 47 mins 20 s) and 32 mins 14 s (range 25 mins 33 s - 44 mins 27 s), respectively.
Our early data show that the novel ATS-Lite strategy produced plans that fulfilled 99.9% of clinical dose constraints in a time frame that is tolerable for patients and comparable to ATP workflows. Therefore, ATS-Lite, which bridges the gap between ATP and full ATS, will be further utilised and developed within our institute and it is a workflow that should be considered for treating patients with HNC on the MRL.
医科达Unity磁共振直线加速器(MR-Linac)已能够对头颈部癌(HNC)患者进行自适应放射治疗(ART)。自适应形状精简版(ATS-Lite)是一种新型的自适应形状策略,可提供ART,且无需临床医生每日在场进行在线靶区和危及器官(OAR)勾画。在本研究中,我们将临床应用的ATS-Lite策略的性能与三种自适应位置(ATP)变体进行了比较:自适应分段(ATP-AS)、优化权重(ATP-OW)和优化形状(ATP-OS)。
两名HNC患者在MR-Linac上接受了根治性剂量放疗。对于每个分次,在线生成并实施一个ATS-Lite计划,并为每个ATP变体离线生成额外的计划。为评估每个分次计划的临床可接受性,对所有四个计划的靶区和OAR的20个临床目标进行了评估。
分析了53个分次。ATS-Lite通过了99.9%的强制剂量约束。ATP-AS和ATP-OW分别有7.6%的强制剂量约束未通过。54 Gy的计划靶体积(D95%和D98%)是ATP最常未通过剂量约束的靶区。患者1和患者2的ATS-Lite中位分次时间分别为40分9秒(范围28分16秒 - 47分20秒)和32分14秒(范围25分33秒 - 44分27秒)。
我们的早期数据表明,新型ATS-Lite策略生成的计划在患者可耐受的时间范围内满足了99.9%的临床剂量约束,且与ATP工作流程相当。因此,填补了ATP和完整ATS之间差距的ATS-Lite将在我们研究所进一步应用和开发,它是一种在MR-Linac上治疗HNC患者时应考虑的工作流程。